Positive high‑level results from the phase 3 OBERON and TITANIA trials indicate that tozorakimab achieved statistically significant and clinically meaningful reductions in the a ...
Johnson & Johnson has announced a landmark regulatory decision that will allow people living with multiple myeloma to administer the subcutaneous formulation of daratumumab themse ...
DNA Script has signed distribution agreements with Gencell, Bio-Medical Science (BMS) and Biostream, expanding global access ...
Laigo Bio has completed the second close of its seed financing round at €5.5m, bringing the total raised to €17m ...
Axplora has announced plans to build a 4,500sqm R&D and laboratory hub at its Farmabios site in Gropello Cairoli in Italy ...
Ondine Biomedical has announced the North American phase 3 study has reached more than 93% enrolment, bringing the company ...
R1 Therapeutics has launched with an oversubscribed $77.5 million Series A financing and an exclusive global licence to ...
AlzeCure Pharma has released new preclinical findings for its lead Alzheimer’s drug candidate, NeuroRestore ACD856, following a presentation at the AD/PD 2026 international conference.
Early trial shows more than 50% LRRK2 reduction and supports expansion into other neurodegenerative conditions ...
Samsung Bioepis has entered a new global agreement with Sandoz to develop and commercialise up to five next‑generation ...
Compressed air is among the largest energy expenses in pharmaceutical manufacturing and must remain entirely ...
AEON Biopharma, a biopharmaceutical company, has appointed John Bencich as Chief Financial Officer (CFO) Bringing more than ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results